---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255167"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:27:46.308040+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23

## Summary
- GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.
- Adjusted gross margin 50.7%; adjusted operating margin 14.9% vs 3.7%.
- Full-year 2024 revenue guidance narrowed to $630-$639M (midpoint unchanged).
- CDMO revenue and orders each grew ~20% YoY; new modalities record quarterly revenue.
- Announced definitive agreement to acquire chromatography firm Tantti Laboratory Inc.

## SEC filing metadata
- accession: 0001193125-24-255167
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312524255167/0001193125-24-255167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312524255167/d811195d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255167
- JSON: https://secwatch.observer/filing/0001193125-24-255167.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.